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Abstract
Neutrophils are known to be targets for the biological activity of
tumour necrosis factor (TNF)-α in the pathogenensis of
rheumatoid arthritis (RA). Therefore, these cells may be among
the targets of anti-TNF-α therapy. In this study we evaluated the
effect of therapy with adalimumab (a fully human anti-TNF-α
mAb; dosage: 40 mg subcutaneously every other week) on
certain phenotypic and functional aspects of neutrophils
obtained from 10 selected patients with RA and 20 healthy
control individuals. Peripheral blood neutrophils were obtained
at baseline and during anti-TNF-α therapy (2, 6 and 12 weeks
after the first administration of adalimumab). All patients had
been receiving a stable regimen of hydroxychloroquine,
methotrexate and prednisone for at least 3 months before and
during the study. Baseline neutrophil chemotaxis was
significantly decreased in RA patients when compared with
control individuals (P  < 0.001). Two weeks after the first
administration of adalimumab, chemotactic activity was
completely restored, with no differences noted between
patients and control individuals; these normal values were
confirmed 6 and 12 weeks after the start of anti-TNF-α therapy.
Phagocytic activity and CD11b membrane expression on
neutrophils were similar between RA patients and control
individuals; no modifications were observed during TNF-α
neutralization. The production of reactive oxygen species, both
in resting and PMA (phorbol 12-myristate 13-acetate)-
stimulated cells, was significantly higher in RA patients at
baseline (P < 0.05) and was unmodified by anti-TNF-α mAb.
Finally, we showed that the activation antigen CD69, which was
absent on control neutrophils, was significantly expressed on
neutrophils from RA patients at baseline (P < 0.001, versus
control individuals); however, the molecule was barely
detectable on cells obtained from RA patients during
adalimumab therapy. Because CD69 potentially plays a role in
the pathogenesis of arthritis, our findings suggest that
neutrophils are among the targets of anti-TNF-α activity in RA
and may provide an insight into a new and interesting
mechanism of action of anti-TNF-α mAbs in the control of
inflammatory arthritis.
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Introduction
Tumour necrosis factor (TNF)-α has been found to play a
central role in the pathogenesis of rheumatoid arthritis
(RA), which has led to the rational development of novel
drug therapies that neutralize the deleterious effects of this
cytokine [1,2]. Several studies have shown dramatic thera-
peutic effects of anti-TNF-α antibodies, both in experimen-
tal collagen-induced arthritis and in the treatment of
inflammatory diseases such as rheumatoid arthritis (RA) [3-
5], psoriatic arthritis [6], juvenile rheumatoid arthritis [7]
and Crohn's disease [8]. The role played by phagocytic
cells in the pathogenesis of these inflammatory diseases
[9-11] and the capacity of TNF-α to prime and/or activate
phagocytic cells [12] suggest, at least in part, that down-
regulation of phagocyte activity may be involved in the
mechanism of action of anti-TNF-α therapy [9].
BSA = bovine serum albumin; C3Zy = C3-coated zymosan; FMLP = N-formyl-methionyl-leucyl-phenylalanine; mAb = monoclonal antibody; MFI = 
mean fluorescence intensity; PBS = phosphate buffered saline; PI = phagocytic index; PMA = phorbol 12-myristate 13-acetate; RA = rheumatoid 
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There is increasing evidence that inhibition of TNF-α may
be associated with the development of adverse conse-
quences such as carcinogenesis, autoimmune disorders
and, importantly, infectious diseases caused by Gram-pos-
itive and Gram-negative bacteria, mycobacteria and fungi
(for review, see Olsen and Stein [2]). Again, the role played
by TNF-α in the activation of phagocytic cells and the
involvement of these cells in the host defence against infec-
tions suggest that impairment in phagocytic cell activity
may heighten the risk for infection during TNF-α neutraliza-
tion [13].
Few data have been reported on the effect of anti-TNF-α
therapy on neutrophil function ex vivo. Decreased influx of
neutrophils in inflamed joints was reported by Taylor and
coworkers [14] in RA patients treated with infliximab (a chi-
meric anti-TNF-α mAb) and by Den Broeder and coworkers
[15] in patients treated with adalimumab (a fully human anti-
TNF-α mAb). However, no significant impairment in ex vivo
neutrophil function was observed in RA patients treated
with etanercept (a soluble human p75 TNF receptor) [16]
or with adalimumab [15].
In this work we evaluated certain phenotypic and functional
aspects of neutrophils obtained from RA patients during
treatment with adalimumab. To this end, chemotaxis,
phagocytosis and reactive oxygen species (ROS) produc-
tion were assessed in peripheral blood neutrophils,
together with membrane expression of CD11b and CD69
– two functionally different activation molecules [17].
Methods
Reagents
The anti-CD69 mAb (IgG2a, clone HP-4B3) was obtained
from Calbiochem (La Jolla, CA, USA). The anti-CD11b was
OKM1 (mouse IgG2 isotype; Ortho Diagnostics, Raritan,
NJ, USA). FITC-conjugated goat anti-mouse IgG was from
Immunotech SA (Marseille, France). Irrelevant class-
matched mAbs were used as controls for nonspecific bind-
ing (Becton Dickinson, San Jose, CA, USA). Lymphoprep
gradient (density 1.077 g/ml) was purchased from Nye-
gaard (Oslo, Norway). RPMI 1640 was obtained from
HyClone Laboratories (Logan, UT, USA). Bovine serum
albumin (BSA), N-formyl-methionyl-leucyl-phenylalanine
(FMLP), phorbol 12-myristate 13-acetate (PMA), lucigenin
(bis-N-methylacridinum nitrate) and zymosan A were from
Sigma Chemical Company (St. Louis, MO, USA).
Patients
Peripheral blood samples were collected from10 selected
and consenting RA patients who satisfied the American
College of Rheumatology 1987 criteria [18], who had
active disease (defined as a disease activity score 28 >
3.2) [19], and who were enrolled in a European open-label,
multicentre, multinational phase IIIb study (the Adalimumab
Research in Active RA [ReAct] study [20]). The study was
approved by the ethical committee of the Ospedale L
Sacco (Milan, Italy). The mean age of the patients was 61.4
years (range 40–83 years); eight were rheumatoid factor
positive and two were rheumatoid factor negative. Three
months before and during the study, all patients received
hydroxychloroquine (200 mg twice daily), methotrexate
intramuscularly (7.5–15 mg/week), and no more than 10
mg/day prednisone. Adalimumab was administered subcu-
taneously every other week (40 mg). Peripheral blood sam-
ples were obtained before anti-TNF-α therapy and
immediately before administration of adalimumab at weeks
2, 6 and 12. Controls were 20 healthy individual who were
matched to the patients with respect to age and sex.
Ex vivo neutrophil function
Peripheral blood neutrophils were obtained by density gra-
dient centrifugation (Lymphoprep) [21]. The purified cells
consisted of a more than 95% pure population of viable
neutrophils, as assessed by morphology and trypan blue
exclusion test.
Neutrophil chemotaxis was evaluated using a modified
Boyden chamber assay, with blind well chambers and 3 µm
micropore filters (Millipore, Bedford, MA, USA) [22].
Briefly, 200 µl of the cell suspension, containing 2.5 × 106
neutrophils/ml in RPMI1640 + 0.4% BSA were layered on
top of the filter, and the lower compartment was filled with
200 µl of the chemotactic factor (see below). Following
incubation at 37°C for 90 min in a humidified atmosphere
with 5% carbon dioxide, the filters were fixed with ethanol
and stained with haematoxylin–eosin. The chemotactic
response was then determined by evaluating the number of
cells × high power field that had migrated through the
entire thickness of the filter; triplicate chambers were used
in each experiment and five fields were examined in each fil-
ter. In all cases the person scoring the assay had no knowl-
edge of the experimental grouping. The chemoattractants
were zymosan-activated serum (1 mg/ml for 30 min at
37°C) at a 10% (vol/vol) final dilution in RPMI 1640, and
the synthetic peptide FMLP at 10-8  mol/l final
concentration.
Phagocytosis was evaluated using C3-coated zymosan
(C3Zy) as particles for uptake [23]. C3Zy was prepared
incubating zymosan in normal human serum (5 mg/ml) for
30 min at 37°C followed by extensive washing. The neu-
trophil suspension (200 µl) was incubated with C3Zy (cell
to particle ratio, 1:5) for 30 min at 37°C in a shaking water
bath. Cytocentrifuge slides of the mixtures were then imme-
diately prepared and stained with May Grunwald–Giemsa.
The number of particles ingested per cell (phagocytic index
[PI]) were established by direct light microscopy (1000 ×
magnification) of at least 200 cells. In all cases the personAvailable online http://arthritis-research.com/content/7/2/R250
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scoring the assay had no knowledge of the experimental
grouping.
Lucigenin-amplified chemiluminescence was used to eval-
uate production of ROS by neutrophils [23]. For the meas-
urement of chemiluminescence, 1 × 105 neutrophils were
mixed in 3 ml polystyrene vials with 5 × 10-5 mol/l lucigenin
in a final volume of 700 µl. The vials were placed in the
Luminometer 1251 (LKB Wallace, Turku, Finland) in the
dark and allowed to equilibrate for 5 min at 37°C with inter-
mittent shaking previously to record the background of the
light output in mV. PMA (final concentration 5 ng/ml) was
added with an appropriate dispenser (1291; LKB Wallace)
and chemiluminescence was recorded continuously. Back-
ground counts were subtracted from the values obtained
after neutrophil stimulation.
Levels of neutrophil membrane expression of CD69 and
CD11b were evaluated as previously reported [23]. Briefly,
2 × 105 neutrophils were washed in phosphate-buffered
saline (PBS) and resuspended with 100 µl PBS containing
0.1% NaN3, 10% human AB serum (to prevent nonspecific
binding of mAb to Fc receptors) and predetermined satu-
rating concentrations of the anti-CD69 or anti-CD11b
mAbs. After incubation for 60 min at 4°C the cells were
washed twice with PBS/NaN3/0.1% BSA and the pellets
were resuspended in 100 µl of the same buffer containing
FITC-conjugated goat anti-mouse IgG in a saturating con-
centration and incubated for 30 min at 4°C. The cells were
then washed twice in PBS and resuspended in 0.5 ml of
ice-cold 2% paraformaldehyde in PBS (pH 7.2). The per-
centage of neutrophils positive for CD69 or CD11b was
quantified within 24 hours on a FACSscan flow cytometer
(Becton Dickinson). A relative measure of antigen expres-
sion was obtained using the mean fluorescence intensity
(MFI), converted from log to linear scale, after subtraction
of the cells' autofluorescence and the fluorescence of cells
incubated with irrelevant isotype control mAbs.
Statistical analysis
Data are expressed as mean ± standard error of the mean.
Statistical analysis was performed using the Student's t-
test for unpaired or paired data as appropriate. P < 0.05
was considered statistically significant.
Results
The chemotactic activity of neutrophils obtained from RA
patients at baseline was significantly impaired as compared
with that in neutrophils from control individuals; the defect
was evident both using zymosan-activated serum (P  <
0.001; Fig. 1) and FMLP (P < 0.02; Fig. 2) as chemoat-
tractant. Two weeks after the start of therapy with adalimu-
mab, the neutrophil chemotactic responsiveness was
significantly improved (Figs 1 and 2), with no differences
between patients and control individuals. The improvement
was evident and persistent during anti-TNF-α therapy at
weeks 6 and 12 (Figs 1 and 2).
The phagocytic capacity of neutrophils was similar
between control individuals (PI 0.99 ± 0.03) and RA
patients at baseline (PI 1.19 ± 0.32), and no changes were
observed during anti-TNF-α therapy (week 2: 1.11 ± 0.03;
week 6: 1.17 ± 0.09; week 12: 1.03 ± 0.04). The CD11b
Figure 1
Effect of adalimumab on neutrophil chemotaxis Effect of adalimumab on neutrophil chemotaxis. Peripheral blood neu-
trophils were purified from 20 controls and 10 patients with rheumatoid 
arthritis (RA) before (baseline) and during therapy with adalimumab at 
weeks 2 (w2), 6 (w6) and 12 (w12). Values represent the number of 
cells migrated × high power field (hpf) using zymosan-activated serum 
(ZAS) as chemoattractant. The dotted lines indicate the mean values.
Figure 2
Neutrophils were obtained as described in the legend to Figure 1 and  then tested for chemotactic responsiveness toward the chemoattract- ant N-formyl-methionyl-leucyl-phenylalanine (FMLP) Neutrophils were obtained as described in the legend to Figure 1 and 
then tested for chemotactic responsiveness toward the chemoattract-
ant N-formyl-methionyl-leucyl-phenylalanine (FMLP). The dotted lines 
indicate the mean values. RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 7 No 2    Capsoni et al.
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molecule was spontaneously expressed on more than 90%
of neutrophils both in control individuals and in RA patients
before and during anti-TNF-α therapy (data not shown).
The level of both spontaneous and FMLP-induced CD11b
membrane expression (MFI) was also similar between con-
trols (MFI for spontaneous: 155.3 ± 3.7; MFI for FMLP-
induced: 591.3 ± 13.9) and RA patients at baseline (MFI
for spontaneous: 159.2 ± 8.5; MFI for FMLP-induced:
558.7 ± 27.1), as well as during adalimumab therapy (MFI
for spontaneous, week 2: 166.3 ± 12.2; MFI for spontane-
ous, week 6: 161.0 ± 16.7; MFI for spontaneous, week 12:
154.4 ± 14.9; MFI for FMLP-induced, week 2: 503.6 ±
33.1; MFI for FMLP-induced, week 6: 547.8 ± 27.7; MFI for
FMLP-induced, week 12: 610.2 ± 41.8).
Both spontaneous and PMA-induced production of ROS
by RA neutrophils was slightly increased at baseline as
compared with controls (P < 0.05) and the differences per-
sisted at all time points examined during adalimumab ther-
apy (Fig. 3).
Although control neutrophils stained with anti-CD69 mAb
yielded very low fluorescence, just above that of unstained
cells (%CD69+ cells: 1.3 ± 0.5; MFI: 1.0 ± 0.3), CD69 was
significantly expressed on neutrophils from RA patients at
baseline (%CD69+ cells: 22.8 ± 5.4; MFI: 7.6 ± 1.4; P <
0.001 versus controls; Fig. 4). As shown in Fig. 4, a signif-
icant inhibition of CD69 expression on RA neutrophils was
induced by adalimumab therapy; the inhibition was already
evident at week 2 after the start of therapy (%CD69+ cells:
5.5 ± 0.9; MFI: 2.6 ± 0.6; P < 0.01 versus RA baseline) but
it was complete at weeks 6 and 12, when no differences
were observed between RA patients and control individu-
als (Fig. 4).
Discussion
The first aim of the study was to determine whether anti-
TNF-α therapy could downregulate neutrophil function,
thus reducing the antimicrobial host defence in patients
with RA. Our ex vivo functional assays do not support this
possibility. In fact, we demonstrated that TNF-α neutraliza-
tion in RA patients did not modify neutrophil activities such
as phagocytosis, which were normal at baseline, or ROS
production, which was slightly increased at baseline. In
agreement with previous studies [24,25], we found
impaired chemotaxis of neutrophils from RA patients
toward two different chemoattractants. Unexpectedly, TNF-
α neutralization induced complete reversal of the neutrophil
chemotactic defect. Various mechanisms may account for
the defective neutrophil migration in RA patients, such as
saturation of membrane receptors with immune complexes
[25], cytokine (TNF-α)-induced desensitization [26-28] and
drug-induced cell toxicity [29-33]. Of particular relevance
are the observations that TNF-α-primed neutrophils are
less responsive to chemoattractants [26-28] and are more
susceptible to the inhibitory effect of methotrexate on
chemotaxis [31]. Because circulating TNF-α has been
demonstrated in RA patients [34], it is possible that anti-
Figure 3
Effect of adalimumab on neutrophil chemiluminescence production Effect of adalimumab on neutrophil chemiluminescence production. 
Neutrophils were obtained as described in the legend to Fig. 1 and 
then tested for chemiluminescence (CL) production in resting condi-
tions (spontaneous CL) or in response to 5 ng/ml phorbol 12-myristate 
13-acetate (PMA-induced CL). Results are expressed as mean ± 
standard error of the mean of peak CL values. *P < 0.05 versus control 
individuals. RA, rheumatoid arthritis.
Figure 4
Modulation of CD69 membrane expression on neutrophils by  adalimumab Modulation of CD69 membrane expression on neutrophils by adalimu-
mab. Neutrophils, obtained as described in the legend to Fig. 1, were 
labelled with anti-CD69 mAb by indirect immunofluorescence. Results 
are expressed as mean ± standard error of the mean of percentage of 
positive cells (% CD69-positive cells) and as mean fluorescence inten-
sity (MFI) corrected for nonspecific staining. *P < 0.001 versus con-
trols; °P < 0.01 versus rheumatoid arthritis (RA) baselineAvailable online http://arthritis-research.com/content/7/2/R250
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TNF-α therapy improves neutrophil migration by removing
the deleterious effect exerted by soluble and/or membrane
bound TNF-α on these cells.
The second aim of the study was to determine whether
downregulation of phagocyte activities are involved in the
anti-inflammatory activity of anti-TNF-α therapy. The lack of
activity on phagocytosis, ROS production or CD11b mem-
brane expression, and the improved migration of neu-
trophils did not implicate neutrophils as targets of the
therapeutic effect of anti-TNF-α. The improved chemotactic
responsiveness we observed in patients during adalimu-
mab therapy does not explain the decreased influx of neu-
trophils into synovial joints previously observed in RA
patients during anti-TNF-α therapy [14,15]. However, there
is evidence that anti-TNF-α mAbs downregulate the
expression of cytokine-inducible adhesion molecules on
endothelial cells [35,36]. The decreased activation of
endothelial cells in the synovial microvasculature, rather
than a defective neutrophil migration, could be responsible
for the decreased homing of neutrophils to the inflamed
joints.
We recently found that both synovial fluid and peripheral
blood neutrophils from RA patients have increased mem-
brane expression of CD69 [37], and this observation was
confirmed in the present study. This activation molecule is
not constitutively expressed on neutrophils but it may be
induced on these cells in vitro by several cytokines, such as
granulocyte–macrophage colony-stimulating factor, inter-
feron-γ and interferon-α [23,38]. Although a specific ligand
for this molecule has not been identified, a role for CD69 in
the pathogenesis of RA was previously suggested by Laf-
fon and coworkers [39], who found that CD69+ T lym-
phocytes were detectable at high levels in synovial fluid and
synovial membrane from RA patients and correlated with
disease activity. Furthermore, Murata and coworkers [40]
recently reported that CD69-null mice were protected from
collagen-induced arthritis, and that transfer of neutrophils
from wild-type mice could restore arthritis in these animals.
These data suggested a crucial role for CD69+ neutrophils
in the pathogenesis of arthritis and implicate the molecule
as a possible therapeutic target for human arthritis. In the
present study we observed that CD69 was downregulated
(or inhibited) on neutrophils from RA patients during adali-
mumab therapy. The mechanism underlying this inhibition is
not clear because, in our experience, TNF-α per se is not
an inducer of CD69 on neutrophils. However, it is possible
that other and as yet undefined CD69 inducers are indi-
rectly inhibited by TNF-α neutralization. In agreement with
our data, Moore and coworkers [41] recently reported
decreased CD69 expression on natural killer cells obtained
from mice treated with anti-TNF-α.
Conclusion
In this study we found that administration of the anti-TNF-α
mAb adalimumab to patients with RA does not interfere
with the neutrophil activities that are required to maintain an
adequate antimicrobial host defence capacity. On the other
hand, the inhibitory activity of the mAb on CD69 membrane
expression on neutrophils indicates that these cells are
among the possible targets of anti-TNF-α activity in RA, and
may provide an insight into a new and interesting mecha-
nism of action of anti-TNF-α mAbs in the control of inflam-
matory arthritis.
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